Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Clinical Trials

Potential treatments for macular degeneration must successfully complete human clinical trials before seeking approval by the U.S. Food and Drug Administration.

Information about clinical trials for the United States as well as clinical trials occurring globally are available at www.clinicaltrials.gov.

We are currently conducting a Phase 2a study of AVA-101 in wet AMD. Learn More.

Avalanche Biotechnologies and the University of Washington Enter Into Exclusive License Agreement to Develop Gene Therapy Medicines to Treat Color Blindness

March 25, 2015

Menlo Park, Calif. and Seattle – March 25, 2015 – Avalanche Biotechnologies (NASDAQ: AAVL) today announced that it has entered into an exclusive license agreement with the University of Washington (UW) in Seattle to develop products based on Avalanche’s proprietary Ocular BioFactory™ Platform for the treatment of color vision deficiency (CVD), commonly known as red-green color blindness.

Read More

Read All Avalanche News